Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CHKA | P35790 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20091075 | 0.77 | IRAK4 (0.33) | — | |
| SCHEMBL3930381 | 0.74 | KDM4E (0.32) | — | |
| SCHEMBL17688749 | 0.70 | HSP90AA1 (0.44) | HSP90AA1HSP90AB1CA2CHKA | |
| SCHEMBL3963194 | 0.69 | L3MBTL1 (0.38) | — | |
| SCHEMBL1022676 | 0.67 | CA2 (0.39) | HSP90AA1HSP90AB1CA2CHKA | |
| SCHEMBL16235040 | 0.66 | CA2 (0.38) | HSP90AA1HSP90AB1CA2CHKA | |
| SCHEMBL16235200 | 0.66 | KDM4E (0.37) | HSP90AA1HSP90AB1CA2CHKA | |
| SCHEMBL20091003 | 0.64 | IRAK4 (0.33) | — | |
| SCHEMBL21859841 | 0.63 | NR1I2 (0.34) | — | |
| SCHEMBL20349163 | 0.62 | GABRB3 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7557103-B2 | Imidazopyridazine compounds | ELI LILLY AND COMPANY (US) | 2009-07-07 | — | — | US | disclosed |
| US-20080153828-A1 | Imidazopyridazine Compounds | ELI LILLY AND COMPANY | 2008-06-26 | — | — | US | disclosed |
| EP-1879896-A1 | IMIDAZOPYRIDAZINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006107784-A1 | IMIDAZOPYRIDAZINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2006-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153828-A1 | Imidazopyridazine Compounds | CRHR1, CRH, CRHR2 | HSP90AA1 2147/4885HSP90AB1 2336/4885CA2 2469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.